Compound I or a pharmaceutically acceptable salt thereof and meropenem for use in a method of treating or ameliorating a bacterial infection in a subject suffering from reduced renal function: wherein: Compound I or the pharmaceutically acceptable salt thereof and meropenem are administered after a dialysis session and wherein: (i) the subject has a creatinine clearance level of equal or greater than 30 ml/min and less than 50 ml/min, and wherein the amount of Compound I or the pharmaceutically acceptable salt thereof is about 1.0 g and the amount of meropenem is about 1.0 g, and wherein Compound I or the pharmaceutically acceptable salt thereof and meropenem are administered every 8 hours (q8h); or, (ii) the subject has a creatinine clearance level of equal or greater than 20 ml/min and less than 30 ml/min, and wherein the amount of Compound I or the pharmaceutically acceptable salt thereof is about 1.0 g and the amount of meropenem is about 1.0 g, and wherein Compound I or the pharmaceutically acceptable salt thereof and meropenem are administered every 12 hours (q12h); or (iii) the subject has a creatinine clearance of equal or greater than 10 ml/min and less than 20 ml/min, and wherein the amount of Compound I or the pharmaceutically acceptable salt thereof is about 0.5 g and the amount of meropenem is about 0.5 g, and wherein Compound I or the pharmaceutically acceptable salt thereof and meropenem are administered every 12 hours (q12h); or (iv) the subject has a creatinine clearance of less than 10 ml/min, and wherein the amount of Compound I or the pharmaceutically acceptable salt thereof is about 0.5 g and the amount of meropenem is about 0.5 g, and wherein Compound I or the pharmaceutically acceptable salt thereof and meropenem are administered every 24 hours (q24h). (i) the subject has a creatinine clearance level of equal or greater than 30 ml/min and less than 50 ml/min, and wherein the amount of Compound I or the pharmaceutically acceptable salt thereof is about 1.0 g and the amount of meropenem is about 1.0 g, and wherein Compound I or the pharmaceutically acceptable salt thereof and meropenem are administered every 8 hours (q8h); or, (ii) the subject has a creatinine clearance level of equal or greater than 20 ml/min and less than 30 ml/min, and wherein the amount of Compound I or the pharmaceutically acceptable salt thereof is about 1.0 g and the amount of meropenem is about 1.0 g, and wherein Compound I or the pharmaceutically acceptable salt thereof and meropenem are administered every 12 hours (q12h); or (iii) the subject has a creatinine clearance of equal or greater than 10 ml/min and less than 20 ml/min, and wherein the amount of Compound I or the pharmaceutically acceptable salt thereof is about 0.5 g and the amount of meropenem is about 0.5 g, and wherein Compound I or the pharmaceutically acceptable salt thereof and meropenem are administered every 12 hours (q12h); or (iv) the subject has a creatinine clearance of less than 10 ml/min, and wherein the amount of Compound I or the pharmaceutically acceptable salt thereof is about 0.5 g and the amount of meropenem is about 0.5 g, and wherein Compound I or the pharmaceutically acceptable salt thereof and meropenem are administered every 24 hours (q24h). <EOS>